Advanced in Ovarian Carcinosarcoma

Dr. Christos Fountzilas

Oncology
Roswell Park Cancer Institute
Elm And Carlton St, 
Buffalo, NY 
Clinical Trials:Currently Recruiting for 2 Trials
Advanced in Ovarian Carcinosarcoma
Roswell Park Cancer Institute
Elm And Carlton St, 
Buffalo, NY 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Christos Fountzilas is an Oncologist in Buffalo, New York. Dr. Fountzilas is rated as an Advanced provider by MediFind in the treatment of Ovarian Carcinosarcoma. His top areas of expertise are Pancreatic Cancer, Colorectal Cancer, Familial Pancreatic Cancer, and Stomach Cancer.

His clinical research consists of co-authoring 65 peer reviewed articles and participating in 13 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article in the study of Ovarian Carcinosarcoma.

Specialties
Oncology
Licenses
Internal Medicine in NY
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
MVP Health
  • EPO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 5 Less Insurance Carriers -

Locations

ROSWELL PARK CANCER INSTITUTE
Elm And Carlton St, Buffalo, NY 14263

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

13 Clinical Trials

A Phase 1/2 Study of M3814 (Peposertib) in Combination With Hypofractionated Radiotherapy for the Treatment of Locally Advanced Pancreatic Adenocarcinoma
A Phase 1/2 Study of M3814 (Peposertib) in Combination With Hypofractionated Radiotherapy for the Treatment of Locally Advanced Pancreatic Adenocarcinoma
Enrollment Status: Recruiting
Publish Date: October 15, 2025
Intervention Type: Drug, Procedure, Other, Radiation
Study Drug: Peposertib
Study Phase: Phase 1/Phase 2
Randomized Phase II Selection Study of Ramucirumab and Paclitaxel Versus FOLFIRI in Refractory Small Bowel Adenocarcinoma
Randomized Phase II Selection Study of Ramucirumab and Paclitaxel Versus FOLFIRI in Refractory Small Bowel Adenocarcinoma
Enrollment Status: Recruiting
Publish Date: July 14, 2025
Intervention Type: Drug, Biological
Study Drugs: Fluorouracil, Irinotecan, Irinotecan hydrochloride, Leucovorin, Leucovorin calcium, Paclitaxel, Ramucirumab
Study Phase: Phase 2
Randomized Phase II Clinical Trial of Olaparib + Pembrolizumab vs. Olaparib Alone as Maintenance Therapy in Metastatic Pancreatic Cancer Patients With Germline BRCA1 or BRCA2 Mutations
Randomized Phase II Clinical Trial of Olaparib + Pembrolizumab vs. Olaparib Alone as Maintenance Therapy in Metastatic Pancreatic Cancer Patients With Germline BRCA1 or BRCA2 Mutations
Enrollment Status: Suspended
Publish Date: October 07, 2025
Intervention Type: Procedure, Drug, Biological
Study Drugs: Olaparib, Pembrolizumab
Study Phase: Phase 2
Randomized Phase II Study of 2nd Line FOLFIRI Versus Modified FOLFIRI With PARP Inhibitor ABT-888 (Veliparib) (NSC-737664) in Metastatic Pancreatic Cancer
Randomized Phase II Study of 2nd Line FOLFIRI Versus Modified FOLFIRI With PARP Inhibitor ABT-888 (Veliparib) (NSC-737664) in Metastatic Pancreatic Cancer
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Drug, Other
Study Drugs: Fluorouracil, Irinotecan Hydrochloride, Leucovorin Calcium, Veliparib
Study Phase: Phase 2
A Phase 1, Open-label, Multiple-ascending Dose Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of KD033 (SAR445710) in Subjects With Metastatic or Locally Advanced Solid Tumors
A Phase 1, Open-label, Multiple-ascending Dose Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of KD033 (SAR445710) in Subjects With Metastatic or Locally Advanced Solid Tumors
Enrollment Status: Terminated
Publish Date: September 16, 2025
Intervention Type: Drug
Study Phase: Phase 1
A Phase II Study of TAS-102, Irinotecan and Bevacizumab in Pre-Treated Metastatic Colorectal Cancer (TABAsCO)
A Phase II Study of TAS-102, Irinotecan and Bevacizumab in Pre-Treated Metastatic Colorectal Cancer (TABAsCO)
Enrollment Status: Completed
Publish Date: August 11, 2025
Intervention Type: Drug, Biological
Study Drugs: Irinotecan, Bevacizumab, Trifluridine, Tipiracil
Study Phase: Phase 2
MOUNTAINEER: A Phase II, Open Label Study of Tucatinib Combined With Trastuzumab in Patients With HER2+ Metastatic Colorectal Cancer
MOUNTAINEER: A Phase II, Open Label Study of Tucatinib Combined With Trastuzumab in Patients With HER2+ Metastatic Colorectal Cancer
Enrollment Status: Completed
Publish Date: November 26, 2024
Intervention Type: Drug
Study Phase: Phase 2
A Phase II Study Evaluating Safety and Efficacy of Niraparib in Patients With Previously Treated Homologous Recombination (HR) Defective or Loss of Heterozygosity (LOH) High Metastatic Esophageal/Gastroesophageal Junction/Proximal Gastric Adenocarcinoma
A Phase II Study Evaluating Safety and Efficacy of Niraparib in Patients With Previously Treated Homologous Recombination (HR) Defective or Loss of Heterozygosity (LOH) High Metastatic Esophageal/Gastroesophageal Junction/Proximal Gastric Adenocarcinoma
Enrollment Status: Terminated
Publish Date: June 04, 2024
Intervention Type: Drug
Study Drug: Niraparib
Study Phase: Phase 2
Perioperative Analysis of Binimetinib and Palbociclib in RAS-Driven Tumors
Perioperative Analysis of Binimetinib and Palbociclib in RAS-Driven Tumors
Enrollment Status: Withdrawn
Publish Date: December 22, 2023
Intervention Type: Drug, Procedure
Study Drugs: Binimetinib, Palbociclib
Study Phase: Early Phase 1
A Phase 1b Study of INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors
A Phase 1b Study of INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors
Enrollment Status: Completed
Publish Date: February 21, 2023
Intervention Type: Drug
Study Phase: Phase 1
A Phase III Multicenter Open-label Randomized Trial to Evaluate Efficacy and Safety of Folfirinox (FFX) Versus Combination of CPI-613 With Modified Folfirinox (mFFX) in Patients With Metastatic Adenocarcinoma of the Pancreas
A Phase III Multicenter Open-label Randomized Trial to Evaluate Efficacy and Safety of Folfirinox (FFX) Versus Combination of CPI-613 With Modified Folfirinox (mFFX) in Patients With Metastatic Adenocarcinoma of the Pancreas
Enrollment Status: Completed
Publish Date: January 03, 2023
Intervention Type: Drug
Study Drugs: CPI 613, mFolfirinox, Folfirinox
Study Phase: Phase 3
A Phase 1b (Open-Label) / Phase 2 (Randomized, Double-Blinded) Study Evaluating Nab-Paclitaxel and Gemcitabine With or Without Olaratumab in the Treatment of First-Line Metastatic Pancreatic Cancer
A Phase 1b (Open-Label) / Phase 2 (Randomized, Double-Blinded) Study Evaluating Nab-Paclitaxel and Gemcitabine With or Without Olaratumab in the Treatment of First-Line Metastatic Pancreatic Cancer
Enrollment Status: Completed
Publish Date: June 28, 2022
Intervention Type: Drug
Study Drugs: Olaratumab, Nab-paclitaxel, Gemcitabine
Study Phase: Phase 1/Phase 2
A Phase IIa Study of Rintatolimod Plus Pembrolizumab in Refractory Metastatic Colorectal Cancer
A Phase IIa Study of Rintatolimod Plus Pembrolizumab in Refractory Metastatic Colorectal Cancer
Enrollment Status: Withdrawn
Publish Date: February 08, 2022
Intervention Type: Other, Drug, Biological
Study Phase: Phase 2
View 11 Less Clinical Trials

65 Total Publications

HERTHENA-PanTumor01: a phase II study of patritumab deruxtecan (HER3-DXd) in previously treated advanced solid tumors.
HERTHENA-PanTumor01: a phase II study of patritumab deruxtecan (HER3-DXd) in previously treated advanced solid tumors.
Journal: Future oncology (London, England)
Published: October 15, 2025
Similar Doctors
Distinguished in Ovarian Carcinosarcoma
Dr. Stacey N. Akers
Gynecologic Oncology | Oncology
Distinguished in Ovarian Carcinosarcoma
Dr. Stacey N. Akers
Gynecologic Oncology | Oncology

Sisters Of Charity Hospital Of Buffalo New York

2157 Main St, 
Buffalo, NY 
 (1.1 miles away)
716-862-1000
Languages Spoken:
English
See accepted insurances

Stacey Akers is a Gynecologic Oncologist and an Oncologist in Buffalo, New York. Dr. Akers is rated as a Distinguished provider by MediFind in the treatment of Ovarian Carcinosarcoma. Her top areas of expertise are Ovarian Cancer, Ovarian Carcinosarcoma, Sertoli-Leydig Cell Tumor, Hysterectomy, and Oophorectomy.

Distinguished in Ovarian Carcinosarcoma
Dr. Peter J. Frederick
Gynecologic Oncology | Oncology | Obstetrics and Gynecology
Distinguished in Ovarian Carcinosarcoma
Dr. Peter J. Frederick
Gynecologic Oncology | Oncology | Obstetrics and Gynecology

Rpci Oncology, PC

21 Porter Ave, 
Jamestown, NY 
 (60.5 miles away)
716-664-1909
Languages Spoken:
English
See accepted insurances

Peter Frederick is a Gynecologic Oncologist and an Oncologist in Jamestown, New York. Dr. Frederick is rated as a Distinguished provider by MediFind in the treatment of Ovarian Carcinosarcoma. His top areas of expertise are Endometrial Cancer, Neonatal Ovarian Cyst, Ovarian Cysts, Oophorectomy, and Hysterectomy.

Distinguished in Ovarian Carcinosarcoma
Dr. Shashikant B. Lele
Gynecologic Oncology | Oncology
Distinguished in Ovarian Carcinosarcoma
Dr. Shashikant B. Lele
Gynecologic Oncology | Oncology
Elm And Carlton Streets, 
Buffalo, NY 
 (1.5 miles away)
716-845-2300
Languages Spoken:
English
See accepted insurances

Shashikant Lele is a Gynecologic Oncologist and an Oncologist in Buffalo, New York. Dr. Lele is rated as an Advanced provider by MediFind in the treatment of Ovarian Carcinosarcoma. His top areas of expertise are Endometrial Cancer, Ovarian Carcinosarcoma, Sertoli-Leydig Cell Tumor, Malignant Mixed Mullerian Tumor, and Oophorectomy.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Fountzilas's expertise for a condition
ConditionClose
View All 8 Advanced Conditions
View All 25 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile